Clover Health Director & 10% Owner Sells $17.2M in Shares Following RSU Vesting
CLOV sits 23% above its 52-week low of $2.12.
Summary
Vivek Garipalli, a Director and 10% owner of Clover Health, disposed of shares valued at $17.2 million, primarily to cover tax obligations following the vesting of restricted stock units.
Key Events · Ownership and Investor Activity · CLOV
-
Significant Share Disposition
Vivek Garipalli, a Director and 10% owner, disposed of shares totaling $17,285,393.
-
RSU Vesting Trigger
The disposition was primarily driven by the vesting of restricted stock units (RSUs).
-
Tax Withholding
A substantial portion of the shares, valued at $4,288,908, was withheld by the company to cover tax obligations related to the RSU vesting.
-
Net Reduction in Holdings
Post-transaction, Garipalli's direct holdings decreased to 10,247,042 shares.
Analysis · CLOV · Finance
This Form 4 filing indicates a significant disposition of shares by Vivek Garipalli, a Director and 10% owner of Clover Health. While the transactions are primarily related to the vesting of restricted stock units and subsequent mandatory tax withholding, the total value of shares disposed, exceeding $17 million, is notable. Although not a discretionary sale signaling a change in conviction, such a large volume of shares entering the market or being withheld can still impact market dynamics and represents a reduction in direct insider ownership. Investors should monitor future insider activity for any discretionary sales.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 30% of the 1759 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.34%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CLOV was trading at $2.60 on NASDAQ in the Finance sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $2.12 to $4.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.